CDC issues guidance on RSV treatment for infants

The Centers for Disease Control and Prevention this week released interim guidance for clinicians with limited access to the monoclonal antibody nirsevimab, which was recently approved to prevent respiratory syncytial virus in children aged 2 and under. The guidance calls for prioritizing 100-milligram doses of the treatment for infants under 6 months old and infants at high risk for severe disease due to underlying health conditions, among other recommendations.